Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 31, 2011Platelets

Genetic polymorphisms in enzymes regulating clopidogrel absorption and metabolism (such as CYP2C19) significantly modify active metabolite concentrations, platelet reactivity, and are associated with ischemic and bleeding complications.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

How do genetic polymorphisms influence on-clopidogrel platelet reactivity and long-term clinical outcomes in patients receiving clopidogrel therapy?

Population

Patients receiving clopidogrel therapy for atherothrombotic disease or undergoing percutaneous coronary…

Design

Review

Authors

GCGianluca CampoMMMatteo MiccoliMTMatteo Tebaldi

Discussion

Loading...

Member takes

Overview

Should not yet alter clopidogrel prescribing; leaves open whether CYP2C19-guided therapy improves outcomes in prospective trials.

Structured PICO

How do genetic polymorphisms influence on-clopidogrel platelet reactivity and long-term clinical outcomes in patients receiving clopidogrel therapy?

P
Population
Patients receiving clopidogrel therapy for atherothrombotic disease or undergoing percutaneous coronary intervention (PCI)
I
Intervention
Clopidogrel therapy in the context of genetic polymorphisms (e.g., CYP2C19, CYP2B6, CYP1A2, CYP2C9, CYP3A4, CYP3A5, PON1) affecting its metabolism
O
Outcome
On-clopidogrel platelet reactivity and long-term clinical outcomes (ischemic and bleeding complications)

Genetic polymorphisms, particularly in the CYP450 system, play a crucial role in determining clopidogrel responsiveness and subsequent risk of ischemic or bleeding events.

Cite This Study

Campo et al. (2011) studied this question.

synapsesocial.com/papers/6a7d5eaa76c74e41c946d7dehttps://doi.org/10.3109/09537104.2011.579648
View Full Paper
Ask AI
Bookmark
Share